Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)

BACKGROUND: Multidrug resistance has been associated with expression of the multidrug resistance protein (MRP). Recently, MRP-expression has been detected in human tumor samples of patients with breast cancer and non-small-cell lung cancer. Since taxoids are the most active drugs in the treatment of both tumor entities, the antitumor efficacies of paclitaxel and docetaxel were compared in nude mice bearing human tumor xenografts that express MRP. MATERIALS AND METHODS: Athymic nude mice (nu/nu) bearing tumor xenografts of parental human sarcoma HT1080 or MRP-expressing HT1080/DR4 cells (as confirmed by Northern blot analysis) were treated with the maximum tolerated doses (MTD) of doxorubicin ([Dx] 10 mg/kg i.v. push), paclitaxel ([PC] 50 mg/kg three-hour i.v. infusion), or docetaxel ([DC] 40 mg/kg three-hour i.v. infusion). In vitro, the activity of doxorubicin, paclitaxel and docetaxel was evaluated by the sulphorhodamine B (SRB) assay using the pyridine analogue PAK-104P (5 microM), a potent inhibitor of MRP-function. RESULTS: At their MTDs both taxoids showed significant activity against MRP-negative HT1080 xenografts with response rates of 80% (40% CR) for PC and 100% (60% CR) for DC. In contrast, DC was significantly more active than PC in nude mice bearing doxorubicin resistant MRP-expressing HT1080/DR4 tumor xenografts (overall response rates: 100% (60% CR) for DC; 10% (0% CR) for PC; 0% for Dx). Since treatment of mice with the MTD of PC or DC yielded similar overall toxicity (maximum weight loss for HT1080: PC 8.6 +/- 2.2%; DC 7.5 +/- 2.2% and for HT1080/DR4: PC 11.6 +/- 3.0%; DC 7.6 +/- 1.8%, respectively), these results demonstrate the increase in the therapeutic index for docetaxel against MRP-expressing tumors. In vitro, HT1080/DR4 cells were 270-fold, 6.4-fold and 2.8-fold more resistant than parental cells to doxorubicin, PC and DC, respectively. Pyridine analogue PAK-104P completely restored drug sensitivity to PC and DC, while no effect of PAK-104P on parental HT1080 cells was observed. CONCLUSIONS: Both taxoids, when given at their MTDs, showed significant efficacy against parental HT1080 tumor xenografts. However, docetaxel at its MTD was significantly more active against MRP-expressing tumor xenografts than paclitaxel. Furthermore, in vitro resistance of HT1080/DR4 cells was higher for PC (6.4-fold) than for DC (2.8-fold). Since PAK-104P completely restored sensitivity to both taxoids, the observed resistance appears to be related to MRP. These data suggest, that docetaxel is not as readily transported by MRP as paclitaxel leading to an increased therapeutic ratio in MRP-expressing tumors in vivo. Therefore, docetaxel may have therapeutic advantages in the clinical treatment of MRP-expressing tumors.     

[NZP], a new radiophase for ceramic nuclear waste forms

The NZP structure is a candidate for immobilization of certain types of nuclear waste. It will incorporate ¹³⁷Cs, ⁹⁰Sr, and a range of other nuclides. The leach resistance of CsZr₂(PO₄)₃ appears to be comparable with that of other phases under consideration for radio-Cs immobilization. This phase can be formed by sintering at ～850°C; it is reasonably refractory, and it is compatible with monazite, a favored immobilizing agent for waste actinides.     

Modified mixed oxide perovskites 0.7Sr(Al1/2B1/2) O3·0.3LaAlO3 and 0.7Sr(Al1/2B1/2) O3·0.3NdGaO3 (B=Ta5+ or Nb5+) for high-T c superconductor substrate applications

Single-crystal fibres of modified strontium aluminium tantalum oxide (1-x)Sr(Al_1/2Ta_1/2) O₃·xLaAlO₃(SAT-LA) and (1-x)Sr(Al_1/2Ta_1/2)O₃·xNdGaO₃ (SAT·NG), and modified strontium aluminum niobium oxide (1-x)Sr(Al_1/2Nb_1/2)O₃·xNdGaO₃(SAT·NG) and (1-x)Sr (Al_1/2Nb_1/2)O₃·xLaAlO₃ (SAN·LA) were grown using a laser-heated pedestal growth technique. 0.7SAT·0.3LA grows congruently and retains a twin free simple cubic perovskite structure (as the SAT) when cooled down to room temperature. 0.7SAT·0.3LA crystals have a moderate dielectric constant ( = 21.7) and low dielectric loss (tan = 7.5 × 10^–5) at 10 kHz and 90 K. The reduction problem of Ta⁵⁺ is eliminated (which is common in the case of SAT growth). 0.7SAT·0.3NG and 0.7SAN·0.3NG have lower melting temperatures and crystal growth is easier. NdGaO₃ addition to the SAT and SAN enhances the potential of SAT and SAN as large-area substrates for high-T _c superconductor growth. However, the dielectric constants increased from -12 to -16(0.7SAT·0.3NG) and from 18 to 23 (0.7SAN·0.3NG) as a result of NdGaO₃ incorporation.     

Hydrothermal Preparation of Ultrafine Ferrites and Their Sintering

Ultrafine and nearly spherical ferrites such as NiFe₂O₄, ZnFe₂O₄, Ni_xZn_1−xFe₂O₄, Mn_0.5Zn_0.5Fe₂O₄, and CoFe₂O₄ were prepared under mild hydrothermal conditions by precipitating from metal nitrates with aqueous ammonia. These hydrothermal ferrite powders were shown to sinter to almost theoretical density at 1000°C without any sintering aids.     

The effect of composition on the superconducting transition temperature in NbNxOy

The existence of superconducting, FCC, nitrogen-rich niobium oxynitride thin films is reported. The superconducting transition temperature, T_c, is observed to increase as the composition approaches NbN_0.90O_0.02.     

Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents

Platinum-type drugs have proven to be valuable in the treatment of a variety of solid tumors, beginning with the commercial approval of cisplatin 18 years ago. There are several clinically important toxicities commonly associated with the administration of these drugs. Despite the extensive use of cisplatin and carboplatin, the fundamental chemical transformations and mechanisms that underlie their antitumor and toxic effects have not been fully characterized. Several first-generation protective thiols have been clinically studied in an attempt to reduce the toxicity of platinum-type drugs; while some of these agents appear to protect against certain toxicities, nearly all platinum-protecting drugs have their own intrinsic toxicities, which can be additive to the toxicity of platinum-type drugs. Tumor protection by platinum-protecting drugs is an additional untoward effect that is associated with certain types of agents and must be addressed with care. Recent advances in theoretical and laboratory methods and the use of supercomputers have extended our understanding of the possible major mechanisms underlying platinum drug antitumor activity and toxicity; we present strong evidence that there are two classes of chemical species of platinum drug. One class appears to predominantly account for the antitumor activity, and the other class of chemical species produces many of the toxic effects of platinum drugs. We have discovered a new nontoxic, second-generation platinum-protecting agent, known as BNP7787, which appears to selectively inactivate and eliminate toxic platinum species. BNP7787 has recently entered phase I clinical testing in cancer patients.     

Sol—Gel Fabrication of Pb(Zr0.52 Ti0.48)O3 Thin Films Using Lead Acetylacetonate as the Lead Source

Lead zirconium titanate (PZT) thin films of the morphotropic phase boundary composition [Pb(Zr_0.52Ti_0.43)O₃] were deposited on platinum-coated silicon by a modified sol-gel process using lead acetylacetonate as the lead source. The precursor solution for spin coating was prepared from lead acetylacetonate, zirconium n -butoxide, and titanium isopropoxide. The use of lead acetylacetonate instead of the widely used lead acetate trihydrate provided more stability to the PZT precursor solution. Films annealed at 700°C for 12 min formed well-crystallized perovskite phase of Pb(Zr_0.52Ti_0.48)O₃. Microstructures of these films indicated the presence of submicrometer grains (0.1 to 0.2 μm). The dielectric constant and loss values of these films measured at 10 kHz were approximately 1200 and 0.04, respectively, while the remanent polarization and coercive field were ∼ 13 μC/cm² and ∼ 35 kV/cm. Aging of the solution had almost no effect on the dielectric and ferroelectric properties of these films.     

Crystallization of Anorthite-Seeded Albite Glass by Solid-State Epitaxy

Stoichiometric albite glass (NaAlSi₃O₈) was seeded with 5 wt% crystalline anorthite (CaAl₂Si₂O₈) to make albite glass-ceramics. The epitaxial crystallization of the albite glass to the glass-ceramics was investigated by X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectrometry (EDS). High albite was observed as the major crystallization product over the temperature range of 800–1200°C. No crystalline albite could be crystallized from pure albite glass without seeds. Small amounts of nepheline (NaAlSiO₄), however, crystallized along with albite after heat treatments at temperatures lower than 1000°C. The platelike microstructure of albite crystals was revealed in the seeded glasses. The albite blades grew epitaxially from the anorthite seeds, and the Ca content decreased in the direction away from the seeds. The degree of crystallization and the grain size were dependent upon the heat treatment conditions. By increasing the particle size of the seed, the crystallization process was retarded and the resultant microstructure was degraded. The seeding efficiency was also lowered by adding nonisostructural hexagonal anorthite seeds which produced less albite but more nepheline crystals. Crystallization of albite glass by seeding with 5 wt% anorthite is much greater than with the surface nucleation which takes place in a homogeneous 95 wt% albite + 5 wt% anorthite glass.     

Solid-State Epitaxial Effects in Structurally Diphasic Xerogel of Pb(Mg1/3Nb2/3)O3

Lead magnesium niobate (PMN), Pb(Mg_1/3Nb_2/3)O₃, with perovskite structure has been prepared using structurally diphasic PMN gels. The diphasic gels were made using various concentrations of perovskite PMN seeds. The unseeded gel calcined at 775°C for 2 h gave ∼98% of perovskite PMN phase. The use of 1% PMN perovskite seed not only led to a pure perovskite phase but also lowered the crystallization temperature of these gels by about 75°C. These results show that isostructural seeding helps to lower the crystallization temperature of perovskite PMN phase.